1. ARRY wants to use the NVS/MEK partnership deal (#msg-49182759) as a model for a potential partnership for ARRY-520 (i.e., ARRY may be willing to sacrifice a higher share of clinical development costs in exchange for co-promotion rights in the U.S.).
2. ARRY sees a big opportunity to potentially combine ARRY-380 with Herceptin and an even bigger opportunity to potentially combine 380 with T-DM1 should both reach the market. ARRY is talking to potential partners and is "getting a lot of interest" in the drug.
Market Data 
Markets 
AI
